SurModics' ($SRDX) revenue cold as Minnesota

As the weather gets bleaker in Minnesota, the Minneapolis Star Tribune is reporting some bleak news about SurModics ($SRDX), an about Eden Prairie-based drug-delivery company. Share price does not tell the whole story about a biotech company, but its stock tumbled 31 percent Thursday, a day after the the company reported results that fell well short of expectations.

The company is blaming the bad economy and the decision to go further into pharma during a time when pharmaceutical R&D is cutting back, according to the article.

The paper reports that SurModics' revenues plunged 19 percent from a year earlier to $15.5 million in the three months ending Sept. 30. The company reported a net loss of $21.7 million, compared with a net income of $2.7 million during the fourth quarter in 2009.

"It's probably a combination of bad choices, bad economy and bad luck," analyst Daniel Owczarski told the paper.

- read the article in the Star Tribune

Suggested Articles

Armed with microrobots and magnetic fields, Pursue scientists are looking to the future of targeted drug delivery, starting with the colon.

Zosano will need to run additional studies and await an FDA inspection to address the agency's complete response letter on its migraine patch Qtrypta.

Nanoform Finland tapped Quotient Sciences to help run the first in-human trial of a drug developed using its 'nanoforming' technology later this year.